349 related articles for article (PubMed ID: 20221638)
1. Increased prevalence of regulatory T cells in the tumor microenvironment and its correlation with TNM stage of hepatocellular carcinoma.
Shen X; Li N; Li H; Zhang T; Wang F; Li Q
J Cancer Res Clin Oncol; 2010 Nov; 136(11):1745-54. PubMed ID: 20221638
[TBL] [Abstract][Full Text] [Related]
2. Inhibiting effect of Astragalus polysaccharides on the functions of CD4+CD25 highTreg cells in the tumor microenvironment of human hepatocellular carcinoma.
Li Q; Bao JM; Li XL; Zhang T; Shen XH
Chin Med J (Engl); 2012 Mar; 125(5):786-93. PubMed ID: 22490576
[TBL] [Abstract][Full Text] [Related]
3. [Clinical significance of regulatory T cells proportion in the peripheral blood and tumor tissue in primary hepatocellular carcinoma].
Li SP; Peng QQ; Ding T; Xu J; Zhang CQ; Feng KT; Li JQ
Zhonghua Zhong Liu Za Zhi; 2008 Jul; 30(7):523-7. PubMed ID: 19062720
[TBL] [Abstract][Full Text] [Related]
4. Expansion of peripheral and intratumoral regulatory T-cells in hepatocellular carcinoma: a case-control study.
Thakur S; Singla A; Chawla Y; Rajwanshi A; Kalra N; Arora SK
Indian J Pathol Microbiol; 2011; 54(3):448-53. PubMed ID: 21934201
[TBL] [Abstract][Full Text] [Related]
5. Comparative analyses of regulatory T cell subsets in patients with hepatocellular carcinoma: a crucial role of CD25(-) FOXP3(-) T cells.
Kakita N; Kanto T; Itose I; Kuroda S; Inoue M; Matsubara T; Higashitani K; Miyazaki M; Sakakibara M; Hiramatsu N; Takehara T; Kasahara A; Hayashi N
Int J Cancer; 2012 Dec; 131(11):2573-83. PubMed ID: 22419479
[TBL] [Abstract][Full Text] [Related]
6. Increased CD4(+) CD69(+) CD25(-) T cells in patients with hepatocellular carcinoma are associated with tumor progression.
Zhu J; Feng A; Sun J; Jiang Z; Zhang G; Wang K; Hu S; Qu X
J Gastroenterol Hepatol; 2011 Oct; 26(10):1519-26. PubMed ID: 21557772
[TBL] [Abstract][Full Text] [Related]
7. Clinical prognostic value of CD4+CD25+FOXP3+regulatory T cells in peripheral blood of Barcelona Clinic Liver Cancer (BCLC) stage B hepatocellular carcinoma patients.
Li F; Guo Z; Lizée G; Yu H; Wang H; Si T
Clin Chem Lab Med; 2014 Sep; 52(9):1357-65. PubMed ID: 24646790
[TBL] [Abstract][Full Text] [Related]
8. Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients.
Fu J; Xu D; Liu Z; Shi M; Zhao P; Fu B; Zhang Z; Yang H; Zhang H; Zhou C; Yao J; Jin L; Wang H; Yang Y; Fu YX; Wang FS
Gastroenterology; 2007 Jun; 132(7):2328-39. PubMed ID: 17570208
[TBL] [Abstract][Full Text] [Related]
9. [Specific suppression in regulatory T cells by Foxp3 siRNA contributes to enhance the in vitro anti-tumor immune response in hepatocellular carcinoma patients].
Zhang HH; Fei R; Xie XW; Wang L; Luo H; Wang XY; Wei L; Chen HS
Beijing Da Xue Xue Bao Yi Xue Ban; 2009 Jun; 41(3):313-8. PubMed ID: 19727215
[TBL] [Abstract][Full Text] [Related]
10. Increased liver-infiltrating CD8+FoxP3+ regulatory T cells are associated with tumor stage in hepatocellular carcinoma patients.
Yang ZQ; Yang ZY; Zhang LD; Ping-Bie ; Wang SG; Ma KS; Li XW; Dong JH
Hum Immunol; 2010 Dec; 71(12):1180-6. PubMed ID: 20870003
[TBL] [Abstract][Full Text] [Related]
11. Regulatory T cells are associated with post-cryoablation prognosis in patients with hepatitis B virus-related hepatocellular carcinoma.
Zhou L; Fu JL; Lu YY; Fu BY; Wang CP; An LJ; Wang XZ; Zeng Z; Zhou CB; Yang YP; Wang FS
J Gastroenterol; 2010 Sep; 45(9):968-78. PubMed ID: 20411280
[TBL] [Abstract][Full Text] [Related]
12. Tumor-Associated Neutrophils Recruit Macrophages and T-Regulatory Cells to Promote Progression of Hepatocellular Carcinoma and Resistance to Sorafenib.
Zhou SL; Zhou ZJ; Hu ZQ; Huang XW; Wang Z; Chen EB; Fan J; Cao Y; Dai Z; Zhou J
Gastroenterology; 2016 Jun; 150(7):1646-1658.e17. PubMed ID: 26924089
[TBL] [Abstract][Full Text] [Related]
13. Increase of CD4+ CD25+ regulatory T-cells in the liver of patients with hepatocellular carcinoma.
Yang XH; Yamagiwa S; Ichida T; Matsuda Y; Sugahara S; Watanabe H; Sato Y; Abo T; Horwitz DA; Aoyagi Y
J Hepatol; 2006 Aug; 45(2):254-62. PubMed ID: 16600416
[TBL] [Abstract][Full Text] [Related]
14. Regulatory T cells in chronic hepatitis B patients affect the immunopathogenesis of hepatocellular carcinoma by suppressing the anti-tumour immune responses.
Zhang HH; Mei MH; Fei R; Liu F; Wang JH; Liao WJ; Qin LL; Wei L; Chen HS
J Viral Hepat; 2010 Mar; 17 Suppl 1():34-43. PubMed ID: 20586932
[TBL] [Abstract][Full Text] [Related]
15. [The frequency, phenotypes and functions of CD4+ CD25+ regulatory T cells in hepatocellular carcinoma patients].
Zhang HH; Fei R; Mei MH; Liao WJ; Wang XY; Cong X; Qin LL; Ji Y; Wang SX; Wei L; Chen HS
Zhonghua Gan Zang Bing Za Zhi; 2007 Apr; 15(4):266-72. PubMed ID: 17456313
[TBL] [Abstract][Full Text] [Related]
16. The impact of CD4+ CD25+ T cells in the tumor microenvironment of hepatocellular carcinoma.
Lee WC; Wu TJ; Chou HS; Yu MC; Hsu PY; Hsu HY; Wang CC
Surgery; 2012 Feb; 151(2):213-22. PubMed ID: 21975289
[TBL] [Abstract][Full Text] [Related]
17. [Clinical significance of the proportion of CD4+CD25+ regulatory T cells in peripheral blood of hepatocellular carcinoma patients: a report of 117 cases].
Peng QQ; Li SP; Xu L; Li JQ
Ai Zheng; 2007 Jul; 26(7):748-51. PubMed ID: 17626752
[TBL] [Abstract][Full Text] [Related]
18. Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma.
Ormandy LA; Hillemann T; Wedemeyer H; Manns MP; Greten TF; Korangy F
Cancer Res; 2005 Mar; 65(6):2457-64. PubMed ID: 15781662
[TBL] [Abstract][Full Text] [Related]
19. CD4(+)CD25(+)CD127(low/-) regulatory T cells express Foxp3 and suppress effector T cell proliferation and contribute to gastric cancers progression.
Shen LS; Wang J; Shen DF; Yuan XL; Dong P; Li MX; Xue J; Zhang FM; Ge HL; Xu D
Clin Immunol; 2009 Apr; 131(1):109-18. PubMed ID: 19153062
[TBL] [Abstract][Full Text] [Related]
20. Intratumoral plasmacytoid dendritic cells as a poor prognostic factor for hepatocellular carcinoma following curative resection.
Zhou ZJ; Xin HY; Li J; Hu ZQ; Luo CB; Zhou SL
Cancer Immunol Immunother; 2019 Aug; 68(8):1223-1233. PubMed ID: 31201473
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
